Merck KGaA: Pimicotinib Improves Symptoms, Joint Function in Follow-up Results from Late-stage Tenosynovial Giant Cell Tumor Trial

07:42 AM EDT, 10/26/2026 (MT Newswires) -- New two-year follow-up results from a late-stage trial of pimicotinib showed that patients with tenosynovial giant cell tumor saw improvements in symptoms and joint function as early as week five, sustained through two years, Merck KGaA (MRK.F) said Monday. New analysis from the phase 3 Maneuver trial found that patients initially randomized to pimicotinib had mean changes from baseline at week 97 of 19.6% in range of motion, -3.9 in stiffness, -3.1 in pain, and +7.4 in physical function. The German science and technology company holds worldwide commercialization rights for pimicotinib, which was developed by Abbisko Therapeutics.